This study, led by Alden Smith, PharmD, Global Head of Health Economics and Outcomes Research at Ascendis Pharma in Palo Alto, Calif., was created to analyze these healthcare costs and daily somatropin use among adults with GHD with Medicaid or commercial health insurance in the United States.
Smith and colleagues conducted a retrospective analysis of claims data from more than 25,000 patients diagnosed with GHD between January 1, 2008, and December 31, 2017. Those with GHD were directly matched to controls without GHD, based on age, gender, plan type (Medicaid vs. commercial health insurance), region and race.
Advertisement
Data show those adults diagnosed with GHD experienced higher rates of endocrine conditions (>68% in adult GHD vs. ≤10% in control group), metabolic conditions (>93% vs. ≤39%), hepatic and renal function conditions (18-23% vs. Growth Hormone Deficiency (GHD)
Mean annual healthcare costs were 4.6 times more significant for adults with GHD in the Medicaid group than controls ($42,309 vs. $9,146). Costs were 4.1 times higher for those with commercial health insurance compared to controls ($30,111 vs. $7,376).
Only 5.8% of adult GHD patients were treated with somatropin in the commercial health insurance cohort, and just 9.5% of adult GHD patients were treated with somatropin in the Medicaid cohort.
“As discussions on the need to treat growth hormone deficiency in adults continue to evolve, this research reinforces the significant economic burden seen in this disease,” Smith said. “Further research is needed to gain insight into reasons for low treatment rates and determine if treatment can reduce this economic burden and improve the comorbidities that adults with GHD experience.”
Source: Eurekalert
